Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Tolerability of CKD-348 vs Co-administration of CKD-828, D097, D337
NCT04587206Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Oct 2020
- Primary completion
- Dec 2020
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CKD-348 in hypertension (HTN) and dyslipidemia (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Curve from time zero to the last measurable concentration at 72 hours and Maximum Plasma Concentration at 72 hours. Started Oct 2020; status: completed.
02
Drugs
CKD-348
03
Conditions
hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on NCT04587206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04587206.